Genetic Toxicology
The Genetic and Cellular Toxicology Program offers a battery of validated genetic toxicology in vitro cell based assays and in vivo assays to meet ICH S2A/S2B Guidelines and REACH testing requirements. The Genetic and Cellular Toxicology Program also has extensive expertise in the conduct of the Ames, micronucleus, and Comet assay and offers flexible protocols combining multiple endpoints with in vitro and in vivo tests. Mechanistically-based assays that are offered include primary cell culture systems, quantitative gene expression profiling, and toxicogenomic studies. Validated genetic toxicology testing conducted under GLP guidelines and novel technologies are integrated to meet the regulatory and research needs of our clients.
Genetic Toxicology Test Battery (ICHS2A and ICHS2B)
- Bacterial Gene Mutation (Ames Assay)
- In vitro Micronucleus by Flow Cytometry or Chromosomal Aberration
- In vivo Micronucleus in Rodents by Flow Cytometry
- In vivo and in vitro Comet Assay
In vitro Chromosomal Aberrations, Micronucleus, and Comet Assay
- V79, CHO, Mouse Lymphoma, and Human TK6 Cells
- Multiplexed Micronucleus and Comet Assay Testing Protocols
- Low Compound Requiring ≤ 50 mg, Rapid Turnaround
- Human Lymphocytes
In vivo Micronucleus and Comet assay
- Flow Cytometry Based Micronucleus Assay in Mice and Rats
- Aneuploidy Assessment by Flow Cytometry and CREST
- Multiple Tissue Comet Assay
- Combined in vivo Micronucleus and Comet Assay Testing Protocols
Other Services Offered
- Transgenic Mouse Models
- Big Blue® Mice and Rats for Gene Mutation
- Short-Term Cancer Models - p53 +/- and rasH2 mice
- In vitro, Multi-Endpoint Assays in Primary Cells and Cell Lines
- Primary Rodent and Human Hepatocytes
- Toxicogenomics Studies Design and Capabilities
- Quantitative Gene Expression Profiling
- Mouse Genomic Analysis
- Genotoxicity Biomarkers
Lead Scientist
Les Recio, Ph.D. DABT
Phone: 919 281-1110 Ext. 716
Email: (JavaScript must be enabled to view this email address)
Dr. Recio is the Director of the Genetic Toxicology division. Dr. Recio is responsibilities at ILS include defining the scope of work, providing oversight and organization for all studies, and training of staff in genetic toxicology methods. He provide supervision of all genetic toxicology projects through prioritization, coordination, and scheduling of all activities and deliverables including data processing and preparation of drafts of study reports, protocols, and publication. Dr. Recio develops capabilities for novel approaches for using the comet assay and micronucleus assays using rapid high-throughput approaches. He interacts with ILS staff to develop new programs and provide new avenues for research projects. Dr. Recio was appointed to the Editorial Board of Toxicological Sciences and was elected to the North Carolina Society of Toxicology Board of Councilors in 2006. After completion of a postdoctoral fellowship in 1989, Dr. Recio became a Senior Research Fellow in the Cellular and Molecular Toxicology Department of the Chemical Industry Institute of Toxicology (CIIT). While at CIIT (1989 to 2002), Dr. Recio’s research group published more than 65 manuscripts in peer-reviewed literature in the area of molecular biology, genetic toxicology, and carcinogenesis. Dr. Recio received both his M.S. and Ph.D in Toxicology from the University of Kentucky.